173 related articles for article (PubMed ID: 32685606)
1. Renal Impairment,
Golan Y; DuPont HL; Aldomiro F; Jensen EH; Hanson ME; Dorr MB
Open Forum Infect Dis; 2020 Jul; 7(7):ofaa248. PubMed ID: 32685606
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of
Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB
Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972
[TBL] [Abstract][Full Text] [Related]
3. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
[TBL] [Abstract][Full Text] [Related]
4. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
[TBL] [Abstract][Full Text] [Related]
5. Genetic Association Reveals Protection against Recurrence of
Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
mSphere; 2020 May; 5(3):. PubMed ID: 32376702
[TBL] [Abstract][Full Text] [Related]
6. Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With
Cornely OA; Mullane KM; Birch T; Hazan-Steinberg S; Nathan R; Bouza E; Calfee DP; Ellison MC; Wong MT; Dorr MB
Open Forum Infect Dis; 2020 Feb; 7(2):ofaa038. PubMed ID: 32099847
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
Johnson S; Citron DM; Gerding DN; Wilcox MH; Goldstein EJC; Sambol SP; Best EL; Eves K; Jensen E; Dorr MB
Clin Infect Dis; 2021 Nov; 73(9):e2616-e2624. PubMed ID: 32735653
[TBL] [Abstract][Full Text] [Related]
8. Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II.
Wilcox MH; Rahav G; Dubberke ER; Gabryelski L; Davies K; Berry C; Eves K; Ellison MC; Guris D; Dorr MB
Open Forum Infect Dis; 2019 Aug; 6(8):. PubMed ID: 31375837
[TBL] [Abstract][Full Text] [Related]
9. A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.
Yee KL; Kleijn HJ; Zajic S; Dorr MB; Wrishko RE
J Pharmacokinet Pharmacodyn; 2020 Apr; 47(2):121-130. PubMed ID: 32048107
[TBL] [Abstract][Full Text] [Related]
10. Bezlotoxumab in Patients with a Primary
Granata G; Schiavone F; Pipitone G
Antibiotics (Basel); 2022 Oct; 11(11):. PubMed ID: 36358149
[TBL] [Abstract][Full Text] [Related]
11. Real-world Experience of Bezlotoxumab for Prevention of
Hengel RL; Ritter TE; Nathan RV; Van Anglen LJ; Schroeder CP; Dillon RJ; Marcella SW; Garey KW
Open Forum Infect Dis; 2020 Apr; 7(4):ofaa097. PubMed ID: 32363211
[TBL] [Abstract][Full Text] [Related]
12. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of
Escudero-Sánchez R; Ruíz-Ruizgómez M; Fernández-Fradejas J; García Fernández S; Olmedo Samperio M; Cano Yuste A; Valencia Alijo A; Díaz-Pollán B; Rodríguez Hernández MJ; Merino De Lucas E; Martín Segarra O; Sáez Bejar C; Armiñanzas Castillo C; Gutiérrez Gutiérrez B; Rodríguez-Pardo D; Ramos Martínez A; De La Torre Cisneros J; López-Medrano F; Cobo Reinoso J
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374989
[TBL] [Abstract][Full Text] [Related]
13. Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies.
Giacobbe DR; Dettori S; Di Bella S; Vena A; Granata G; Luzzati R; Petrosillo N; Bassetti M
Infect Dis Ther; 2020 Sep; 9(3):481-494. PubMed ID: 32632582
[TBL] [Abstract][Full Text] [Related]
14. Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection.
Kelly CP; Poxton IR; Shen J; Wilcox MH; Gerding DN; Zhao X; Laterza OF; Railkar R; Guris D; Dorr MB
Clin Infect Dis; 2020 Jun; 71(1):81-86. PubMed ID: 31628838
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis.
Akiyama S; Yamada A; Komaki Y; Komaki F; Micic D; Sakuraba A
J Clin Gastroenterol; 2021 Jan; 55(1):43-51. PubMed ID: 32053529
[TBL] [Abstract][Full Text] [Related]
16. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
Madoff SE; Urquiaga M; Alonso CD; Kelly CP
Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
[TBL] [Abstract][Full Text] [Related]
17. Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials.
Basu A; Prabhu VS; Dorr MB; Golan Y; Dubberke ER; Cornely OA; Heimann SM; Pedley A; Xu R; Hanson ME; Marcella S
Open Forum Infect Dis; 2018 Nov; 5(11):ofy218. PubMed ID: 30460321
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review.
Thandavaram A; Channar A; Purohit A; Shrestha B; Patel D; Shah H; Hanna K; Kaur H; Alazzeh MS; Mohammed L
Cureus; 2022 Aug; 14(8):e27979. PubMed ID: 36120235
[TBL] [Abstract][Full Text] [Related]
19. Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III).
Sferra TJ; Merta T; Neely M; Murta de Oliveira C; Lassaletta A; Fortuny Guasch C; Dorr MB; Winchell G; Su FH; Perko S; Fernsler D; Waskin H; Holden SR
J Pediatric Infect Dis Soc; 2023 Jun; 12(6):334-341. PubMed ID: 37389891
[TBL] [Abstract][Full Text] [Related]
20. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
Goldstein EJC; Citron DM; Gerding DN; Wilcox MH; Gabryelski L; Pedley A; Zeng Z; Dorr MB
Clin Infect Dis; 2020 Aug; 71(4):1102-1105. PubMed ID: 31883370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
